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930A Modified Haploidentical Nonmyeloablative
Transplantation without T Cell Depletion for high-Risk
Acute Leukemia: Successful Engraftment
and Mild GVHD
Mei Guo,1 Zhao Sun,2 Qi-Yun Sun,1 Qin Han,2 Chang-Lin Yu,1 Dan-Hong Wang,1
Jian-Hui Qiao,1 Bin Chen,2 Wan-Jun Sun,1 Kai-Xun Hu,1 Guang-Xian Liu,1 Bing Liu,3
Robert Chunhua Zhao,2 Huisheng Ai1Severe graft-versus-host disease (GVHD) and graft rejection still remain major complications of haploident-
ical nonmyeloablative (NMA) stem cell transplantation. Recent studies have shown that bone marrow-de-
rived mesenchymal stem cells (MSCs) possess immunomodulatory capacity and may promote
hematopoietic engraftment. The purpose of this study was to observe if the new strategy, which included
a haploidentical peripheral blood stem cell transplantation (PBSCT) combined with MSCs, modified NMA
conditioning, and GVHD prophylaxis would improve donor engraftment and prevent severe GVHD. The
modified conditioning approach consisted of fludarabine (Flu), low-dose total body irradiation (TBI), cyclo-
phosphamide (Cy), cytarabine, and anti-Tcell-lymphocyte globulin, whereas the GVHD prophylaxis con-
sisted of cyclosporin A (CsA), mycophenolate mofetil (MMF), anti-CD25 antibody and intrabone marrow
injection of MSCs. Thirty-three patients with high-risk acute leukemia underwent transplantation with
PBSC from HLA-haploidentical donors without T cell depletion. All of the patients achieved full donor chi-
merisms, including 6 who switched to full donor chimerisms from mixed chimerisms in 1 to 2 months after
the transplantations. Rapid hematological engraftment was observed with neutrophils.0.5 109/L at day 11
and platelets .20 109/L at day 14. Fifteen patients (45.5%) developed grade I–IV acute GVHD (aGVHD)
and only 2 (6.1%) developed grade III to IV aGVHD. Nine (31%) of 29 evaluable patients experienced chronic
GVHD (cGVHD). Upon follow-up for 1.5 to 60months, 20 (60.6%) patients were alive andwell and 6 (18.2%)
had relapsed leukemia in the 33 patients. The probability of 3-year survival was 57.2%. The results indicate
that this new strategy is effective in improving donor engraftment and preventing severe GVHD, which will
provide a feasible option for the therapy of high-risk acute leukemia.
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Biol Blood Marrow Transplant 15:930-937, 2009 931Haploidentical NSTwith MSCs for Leukemia[1,2]. Recently, several approaches such as T cells or
CD3/CD19 cell depletion, the use of a ‘‘megadose’’ of
stem cells, and nonmyeloablative (NMA) conditioning
regimens have been employed and showed a significant
decrease of GVHD and treatment-related mortality
(TRM) [3-9]. But graft rejection and severe GVHD
still remain major barriers in haploidentical transplan-
tation, particularly in the setting of NMA stem cell
transplantation (NST).
It has been proven that bonemarrow (BM)-derived
MSCs can promote hematopoietic recovery, improve
donor engraftment [10-13], and possess immunoregu-
latory capacities on multiple immune cell lineage in
allogenic identical or haploidentical transplantation
[14-20]. However, it is still unclear whether MSCs
will improve engraftment and reduce severe acute
GVHD (aGVHD) in the setting of NMA haploident-
ical transplantation. Our previous experiments in
a rhesus monkey model of NMA haploidentical trans-
plantation showed that intrabone marrow injection
(IBMI) ofMSCs could prevent severe aGVHDand en-
hance donor engraftment. Our previouse phase I clin-
ical trial with it had also already proved the safety of its
clinical use [21,22]. Based on the preceding facts, we
designed a new haploidentical NST regimen that con-
sisted of a haploidentical peripheral blood stem cell
transplantation (PBSCT) combined with IBMI of do-
nor-derived MSCs, modifiied NMA conditioning, and
GVHD prophylaxis to observe if it will further im-
prove donor engraftment and prevent severe aGVHD.PATIENTS AND METHODS
Patients
Thirty-three patients with high-risk acute leuke-
mia, aged 7 to 43 years (median 23 years), including
24 males and 9 females, who needed transplantation,
but lacked HLA identical donors, were enrolled in
this study in the 2 participating centers fromDecember
2003 to October 2008. The diagnoses were based on
the French-American-British criteria (FAB) and were
confirmed by immunophenotype and cytogenetic anal-
yses. Fourteen had acute myelogenous leukemia
(AML), 16 were acute lymphoid leukemia (ALL), and
the other 3 had chronic myelogenous leukemia
(CML) in accelerate phases. Of the 33 patient/donor
pairs, 19 (57.6%) were mismatched in 3 HLA loci, 10
(30.3%) in 2 loci, and 4 (1.2%) in 1 locus. Detailed in-
formation about the patients is listed in Table 1.
Institutional Ethics Committee approval was pro-
vided by the 2 participating centers: the AffiliatedHos-
pital of the Academy of Military Medical Sciences, and
the Chinese Academy of Medical Sciences. Patients or
legal guardians of the patients provided written
informed consents for their inclusion in the study.
Written informed consents in accordance with theDeclaration of Helsinki were also obtained from the
donors by an independent physician trained to explain
risks associated with MSCs.Culture of MSCs
MSCs were isolated and propagated from BM by
puncturing posterior iliac crests of the original donors
at 4 to 5 weeks prior to the transplantations as de-
scribed previously [23-25]. All procedures were carried
out under strict Good Manufacture Practice (GMP)
criteria. Briefly, BM aspirates were collected, mononu-
clear cells (MNC) were fractionated with a 1.077 g/
mL Ficoll-Paque density gradient and then cultured
in Dulbecco’s Modified Eagle Medium (DMEM,
Gibco, Rockville, MD) supplemented with 10% fetal
bovine serum (FBS, Gibco) at 37C in a humidified en-
vironment containing 5% CO2. After culturing for 24
to 48 hours, nonadherent cells were removed and the
adherent layer was further cultured until 70% to
80% confluence. Then MSCs were harvested and
used at passages 3 to 5. The surface markers of
MSCs were examined by a 4-color flow cytometer
(EPICSxL-MCL, Beckman Coulter, Fullerton, CA),
including Flk-1 (Santa Cruz Biotechnology, Santa
Cruz, CA), CD29, CD34, CD44, CD45, CD105,
andHLA-DR. Adipogenic differentiation was assessed
by oil red O staining and osteogenic differentiation
was analyzed by von Kossa method. MSCs were also
examined for bacteria and mycoplasma contamination
before use. They were resuspended in 0.5 mL of 0.9%
sodium chloride and administrated by means of IBMI
into the right posterior iliac crests 4 hours prior to
infusion of HSC at day 0.NMA Conditioning
The modified NMA conditioning regimen was
based on our previous protocol for HLA-matched
NMA SCT and a preclinical study on a Rhesus model
[22,26]. It consisted of fludarabine (Flu) 30 mg/m2/day
(days 26 to 22), total body irradiation (TBI; 60Co)
2 Gy (day 21), cyclophosphamide (Cy) 40 mg/kg/
day (days 24, 22), cytarabine (Ara-C) 2.0 g/m2 (days
26 to 23), and rabbit antihuman thymocyte globulin
(ATG) 1.5~2.0 mg/kg/day (days 24 to 21) Figure 1.GVHD Prophylaxis
All of the 33 patients received GVHD prophylaxis,
which consisted of cyclosporine A (CsA) 3 mg/kg/day
i.v. from day24 to21, and adjusted to 1.5 mg/kg/day
from day 0, mycophenolate mofetil (MMF) 30 mg/kg/
day orally from day 25, and anti-CD25 antibody
1 mg/kg (an anti-IL-2 receptor antibody, Hoffmann-
La Roche Corp., Nutley, NJ) on days 1, 3 and 8.
CSA and MMF were tapered off after 150 to 180
days if no aGVHD was observed.
Table 1. Demographic and Transplant Characteristics of Patients and Donors
Case Sex/Age
Diagnosis and
stage of disease
Blast at
transplant(%) Donor/Age HLA mismatch MNC 108/kg CD34 106/kg CD3 108/kg MSC 105/kg
1 M/9 AML-RL2 6.0 Mother/37 A,B,DR 6.8 2.8 1.9 2.0
2 M/24 AML-RL2 6.5 Mother/53 A,B,DR 6.8 4.0 2.3 1.2
3 F/34 AML-RF 22.0 Brother/27 A,DR 5.6 4.4 1.1 17
4 M/11 AML-RF† 14.5 Mother/38 A,B,DR 7.6 5.7 2.7 10
5 F/26 AML-RF 30.0 Brother/28 A,DR 7.8 4.8 1.9 3.4
6 F/23 AML-RL1 24.5 Brother/22 B,DR 6.9 4.8 2.3 2.2
7 M/29 AML-RL1 10.5 Sister/38 DR 8.5 2.2 1.5 0.6
8 F/16 AML-RF† 66.0 Mother/41 A,B,DR 8.5 4.2 1.4 1.2
9 M/16 AML-CR2 5.0 Mother/41 A,B,DR 11.6 7.5 5.2 0.9
10 M/18 AML-CR2 4.5 Father/51 A,B,DR 8.6 5.6 1.6 3.1
11 F/14 AML-CR1‡ 4.0 Father/42 A,B,DR 8.3 2.8 2.4 5.0
12 M/26 AML-CR1* 4.5 Brother/22 B,DR 4.1 5.8 1.4 5.0
13 M/35 AML-CR1*,† 3.5 Brother/40 DR 46.3 7.5 1.2 3.2
14 M/55 AML-CR1* 3.0 Son/28 A,B,DR 8.7 4.2 1.3 4.0
15 M/19 CML-AP 2.5 Brother/28 A,DR 10.1 6.7 1.9 4.4
16 M/23 CML-AP 14.5 Brother/27 B,DR 6.9 3.9 2.6 5.0
17 M/34 CML-AP 5.0 Brother/41 B,DR 6.9 5.3 2.1 2.6
18 M/28 ALL-RL3 28.0 Sister/31 A,B,DR 9.1 1.4 2.8 0.5
19 M/33 ALL-RL1 17.0 Brother/26 B,DR 7.3 2.3 2.7 0.5
20 M/17 ALL-CR4 4.5 Father/42 A,B,DR 5.6 4.3 1.6 5.4
21 M/7 ALL-CR2 2.0 Mother/34 A,B,DR 6.5 4.4 1.3 5.0
22 M/15 ALL-CR2 3.5 Brother/19 A,B,DR 7.1 4.1 1.8 3.9
23 M/17 ALL-CR2 2.6 Mother/43 DR 8.4 4.2 3.9 4.7
24 F/31 ALL-CR2 3.0 Sister/28 A,B,DR 8.8 4.8 1.7 1.2
25 F/38 ALL-CR1‡ 2.5 Son/17 A,B,DR 6.6 4.2 2.1 3.0
26 M/37 ALL-CR1* 4.5 Brother/32 A,B,DR 4.8 5.4 1.8 1.6
27 M/34 ALL-CR1‡ 3.5 Sister/29 A,B,DR 6.7 1.7 2.1 6.3
28 M/14 ALL-CR1‡ 4.0 Father/42 B 3.7 4.5 1.5 3.6
29 F/23 ALL–CR1† 3.5 Mother/49 A,B,DR 5.7 1.1 1.8 3.8
30 F/19 ALL-CR1* 3.5 Sister/25 A,B,DR 6.8 2.6 2.5 3.2
31 M/43 ALL-CR1* 1.5 Brother/48 A,B,DR 6.6 3.9 2.0 2.8
32 M/19 ALL-CR1* 2.5 Father/48 B,DR 9.9 3.1 3.3 2.5
33 M/25 ALL-CR1*,‡ 2.5 Father/48 B,DR 8.5 4.4 2.5 2.7
MNC indicates mononuclear cells; MSC, mesenchymal stem cells; F, female; M, male; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leu-
kemia; CR1: first complete remission; CR2,4, second or four complete remission; RL, relapsed leukemia; FL2,4, second or four relapsed; RF, refractory
leukemia; CML-AP: chronic myelogenous leukemia with accelerate phase.
*Expression of BCR-ABL gene.
†Secondary acute leukemia with myelodysplastic syndrome.
‡White blood cells count >100 x 109/L at diagnosis.
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PBSCs of haploidentical donors were obtained by
a CS-3000S cell separator (Baxter, Deerfield, IL) after
subcutaneous injections of granulocyte-colony stimulat-
ing factor (G-CSF)5 mg/kg twiceaday for4days (filgras-
tim, Kirin Corp., Tokyo, Japan). The infused dosages of
MSCs, MNC, and CD341 cells are listed in Table 1.
Hematologic Recovery and GVHD Grading
The time of neutrophil and platelet recovery was
defined as the first of the 3 consecutive days in which
the absolute neutrophil count exceeded 0.5 109/L
and platelet exceeded 30 109/L. aGVHDwas graded
as 0-IV, whereas grade III-IV was considered to be se-
vere aGVHD [27]. Chronic GVHD (cGVHD) was
graded as limited or extensive in patients who survived
more than 100 days with evidence of engraftment.
Supportive Care
All patients had multilumen indwelling central ve-
nous catheters and were kept in separate rooms. Theywere supported with irradiated blood components in
an attempt to maintain the hematocrit .25% and
the platelet count .10 109/L or to treat bleeding
complications because of thrombocytopenia. Re-
combinant hematopoietic growth factors (filgrastim,
Kirin Corp.) were administered routinely. Supportive
care also included the use of ganciclovir with or with-
out intravenous immunoglobulin for cytomegalovirus
(CMV) reactivation and trimethoprim-sulfamethoxa-
zole for Pneumocystis carinii pneumonia prophylaxis.Detection of Donor Chimerisms of HSCs
and MSCs
Peripheral blood (PB) samples were collected on
day 114, and in 1, 3, and 6 months after transplanta-
tion. Donor engraftment and chimerisms were
assessed by a short tandem repeat-polymerase chain
reaction (STR-PCR) analysis as previously described
[22,26]. Briefly, DNA was extracted from blood sam-
ples of the donors and the patients routinely before
transplantation, then 8 or 9 STR loci (D5, D8, D7,
Biol Blood Marrow Transplant 15:930-937, 2009 933Haploidentical NSTwith MSCs for LeukemiaD13, T, F13, D16, D1, and sex) were amplified by
a PCR-based analysis. At least 2 informative alleles
were chosen for each patient according to the poly-
morphic loci of the donors and the recipients. PCR
products were separated by 6% polyacrylamide gel
electrophoresis, stained with silver nitrate, and then
analyzed by a gel-pro-analyzer. The results were com-
pared with those of the donors and recipients before
transplantation to determine the chimerisms. Donor
cells.95% in total MNCmeans full donor chimerism
(FDC), whereas those at 2.5% to 95% means mixed
chimerisms (MC).
Among the 33 patients, 9 who had mismatched sex
donors underwent BM aspiration, and then MSCs
were expanded in vitro to assess the chimerisms of
stromal cell compartment in 1, 3, 6, and 12 months
posttransplantation by a STR-PCR assay [21].
Analysis of Cellular Immunity
Cellular immunity of the patients was monitored
by flow cytometry using fluorecein dye labeled mono-
clonal antibodies (mAbs) directed to surfacemarkers of
lymphocytes, including CD3, CD4, CD8,
CD(161 56), CD19, CD25, and HLA-DR. Ten
thousands cells were acquired for each acquisition;
the percentage of positive cells and the mean intensity
of fluorescein (MFI) were recorded and analyzed.
Statistical Analysis
Statistical analysis was performed with SAS soft-
ware, version 9.0 (SAS Institute, Cary, NC). Survival
data were analyzed by the Kaplan-Meier method. Sur-
vival curves were compared by means of the log-rank
test or 22 log(LR). A Fisher test was used to assess
the probability of significant differences between
the 2 groups. Statistical significance was defined as
P\ .05.RESULTS
Hematopoietic Recovery and Chimerisms
No MSC infusion-related complications were
observed after the transplantations. The median timeFigure 1. Sketch of nonmyeloablative conditioning Conditioning consisted o
2Gy (day -1), cyclophosphamide (CTX) 40 mg/kg/d (days -4, -2), Ara-C (cyta
globulin (ATG, France) 1.5~2.0 mg/kg/d (days -4 to -1). Abbreviations: CSA
antibody.of neutrophil increased to 0.5 109/L was 11 days
(range: 8-18 days) and that of platelet increased to
30 109/L was 14 days (range: 2-46 days). Delayed
platelet recovery (.30 days) was observed in 4 of the
33 patients. All of the 33 patients achieved FDC, in-
cluding 6 ones who achieved FDC from MC between
30 and 60 days after transplantation.GVHD
Fifteen (45.5%) of the 33 patients developed
aGVHD between 27 to 82 days after transplantation,
including 7 with grade I, 6 with grade II and 2
(6.1%) with grade III or IV aGVHD, and the other
18 patients had no aGVHD. Nine (31%) of the 29
evaluable patients experienced chronic GVHD.Leukemia Relapse
Six (18.2%) of the 33 patients relapsed between 2
to 7.5 months after transplantation. Two of them
achieved a second complete remission by withdrawing
immunotherapy agents or after a second transplanta-
tion: 1 survived and the other 1 died of severe pulmo-
nary infection afterward. The other 4 received regular
chemotherapy but had no responsiveness.Survival
Upon following-up for 1.5 to 60 months, 20
(60.6%) of the 33 patients were alive well. As shown
in Figure 2, the probability of 3-year leukemia-free
survival (LFS) was 57.2% in the 33 patients. The prob-
ability of 3 year LFS in AML patients was 68.6%,
which was significantly higher than that in the ALL pa-
tients (45.0%, P5 .024).MSCs Engraftment
Nine of the 33 patients were assessed for donor
chimerisms in the stromal cell compartment. Four of
them had lower donor MSCs chimerisms at different
time points (1, 3, 6, and 12months posttransplantation
(Table 2). The other 5 patients detected no donor
MSCs chimerisms.f fludarabine 30 mg/m2/d (days -6 to -2), total body irradiation (60Co)
rabine) 1.52.0 g/m2(days -6 to -3), and rabbit anti-human thymocyte
, cyclosporin A; MMF, mycophenolate mofetil; CD25Ab, anti CD25
Figure 2. Probability of leukemia-free survival after transplantation.
The follow-up 1.5-60 months, 20 (60.6%) of thirty-three patients were
still alive well. As shown in Figure 2, The probability of 3 year leukemia-
free survival in AML patients was 68.0%, which was significantly higher
than that ALL patients (45.0%, P5 0.014).
934 Biol Blood Marrow Transplant 15:930-937, 2009M. Guo et al.Immunologic Reconstitution
The results of immunologic constitutions are listed
in Table 3, which shows that there were no significant
changes of CD31CD41, CD31CD41CD251, and
CD31CD191 cells, plus the CD4/CD8 ratio in their
peripheral blood up to 12months after transplantation,
butCD31CD81, CD32CD(161 56)1 andCD31CD
(161 56)1 cells were upregulated in 1 to 3months after
transplantation.DISCUSSION
Haploidentical transplantation is still largely disap-
pointing mainly because of high mortality fromT cell-
mediated alloreactions in lethal GVHD even T cells
depletion or ‘‘megadose’’ of stem cells are used [4-
6,9,28,29]. Many studies have shown that about 26%
to 56% of patients with leukemia and myeloma devel-
oped grade II-IV aGVHD after haploidentical trans-
plantation with CSA and MMF or MTX as GVHD
prophylaxis [1,6,8,28, 30]. In this present study, all of
the 33 patients received haploidentical NST with the
modified GVHD prophylaxis and only 6.1% of them
developed grade III-IV aGVHD, although the overall
rate of aGVHD was 45.5%, which was much better
than any of the results thus reported. The results indi-
cate that the new GVHD prophylaxis with ATG,
CD25, CSA, MMF, plus MSCs is effective in prevent-
ing lethal aGVHD. It has been well investigated that
ATGmay remain in vivo for amuch longer time,which
is beneficial for in vivo T cell depletion and conse-
quently for prevention of aGVHD, whereas anti-
CD25 antibody has similar capacity in treating and
preventingGVHD[31-34]. So it is important to under-
stand their contribution in preventing severe GVHDin this study. AlthoughMSCs possess inhibitory effects
on a variety of immune cells (T cells, B cells, NK cells,
andDC) in terms of their proliferation, differentiation,
maturation, and secretion [35,36], its effects on the
prevention of severe GVHD has also been proved.
Le Blanc [19] reported that refractory GVHDwas sig-
nificantly alleviated in a patient received haploidentical
MSCs. Le Blanc et al [37] also demonstrated that, in
a phase II clinical trial, infusion ofMSCwas an effective
therapy for patients with steroid-resistant GVHD.
Similar facts were also observed in our previous studies
[22] on a monkey model of NMA haploidentical trans-
plantation,which showed that cotransplatation ofHSC
with IBMIofMSCshadmuch sustained donor engraft-
ment and mild GVHD in comparison with that with-
out MSCs. All of these suggest that the infusion of
donor-derived MSCs may play a considerable role in
preventing severe GVHD. For further investigation,
a randomized clinical trial in a double-blind session
with or without IBMI ofMSCs for prevention or treat-
ment of GVHD is carrring out in the China NST
cooperative group now.
Donor T cell depletion (TCD) or ‘‘megadose’’ of
hematopoietic stem cells were usually employed to
overcome HLA barrier[1,2,4,5,8,38]. However, the
benefit of decreased incidence of GVHD from donor
TCD was often companied by the cost of higher rate
of graft rejection, leukemia relapse, and infection, par-
ticularly in the setting of NST [2,5,6,8,30]. Handgre-
tinger et al [39] reported that 17% in 38 patients
with hematologic diseases had graft failure after hap-
loidentical NST with Flu, thiotepa, Mel, and TCD
as conditioning regimen. O’Donnell et al [9] reported
that 31% in 13 patients with leukemia and MDS had
graft failure after haploidentical NST with Flu, low-
dose TBI, and Cy for conditioning. In this study, 33
patients received haploidentical NST with Flu, Ara-
C, and low-dose ATG, Cy, TBI, plus MSCs as the
modified conditioning regimen. All of them achieved
sustained full donor engraftment, including 6 who
achieved FDC from MC between 1 to 2 months after
transplantation. In accordance with a sustained en-
graftment, hematopoietic recovery was also fast and
the time with absolute neutrophil count (ANC)
. 0.5 109/L was 11 days and that with platelet
.30.0 109/L was 14 days. The results suggest that
the modified NMA conditioning regimen without
TCD seems to be enough to achieve sustained donor
engraftment in which the IBMI of MSCs may also
play an important role.
Another important finding worthy of note in this
study was that the 33 patients had a low relapse rate
(18.2%) and a high 3-year survival (57.2%), among
whom 17 AML patients had a higher 3-year survival
rate (68.0%) than that in the ALL patients (45.0%),
despite all of them belonged to high-risk or refrac-
tory/relapsed acute leukemia. This result was much
Table 2. The Outcome of Transplantations in 33 Patients
Case
ANC
>0.5 x 109/L(day)
Platelets
>30x109/L(day)
HSC
chimerism MSC chimerism
aGVHD
grade/time cGVHD
Relapse
(M)
Outcome
posttransplant
1 13 12 MC, FDC Pos,90d, 180d,360d No extensive No Alive, 60 M
2 12 11 FDC ND II,36d lim No Alive, 56 M
3 12 14 FDC Pos,90d, 180d No No 7.5 Dead, Relapse, 9 M
4 10 10 MC-FDC Neg II,46d No No Alive, 50 M
5 9 16 FDC ND III,31d No No Dead, GVHD 3M
6 14 17 MC-FDC ND No lim No Alive, 23 M
7 13 21 FDC Pos,30d No No 5.0 Dead, Relapse, 7 M
8 8 11 FDC ND No No No Dead, Infection, 6 M
9 11 16 FDC Pos,180d No lim No Alive, 43 M
10 18 30 FDC ND II,78d No No Dead, Infection, 4 M
11 10 10 FDC Neg I,28d lim No Alive, 22 M
12 10 6 FDC ND No ext No Alive, 28 M
13 11 16 FDC ND I,45d No No Alive, 8 M
14 10 12 FDC ND I,36d No No Alive, 3.5
15 16 39 FDC ND No lim No Alive, 25 M
16 11 15 FDC ND II,41d No No Alive, 18 M
17 10 8 FDC ND No No No Alive, 18 M
18 11 14 FDC Neg No No 2.0 Dead, Relapse, 3.5 M
19 11 18 MC-FDC ND VI,36d No No Dead,GVHD, 1.5 M
20 14 8 FDC ND II,28d No 3.0 Dead,Relapse, 6.5 M
21 11 8 MC-FDC Neg II,27d No No Dead, Infection, 4 M
22 14 46 MC-FDC ND I, 82d No No Alive, 23 M
23 13 8 FDC ND I,78d lim No Alive, 20 M
24 9 35 FDC ND I,31d No No Alive, 18.5 M
25 11 9 FDC Neg No No 16 Alive, 25M, CR2
26 12 22 FDC ND No No No Dead, Infection, 5 M
27 11 19 FDC ND No No 6.0 Dead,Relapse, 7 M
28 10 4 FDC ND No lim No Alive, 24 M
29 10 12 FDC ND No No No Dead, Infection, 2.5 M
30 13 2 FDC ND I,42d No No Dead, Infection, 3 M
31 11 33 FDC ND No No No Alive, 7 M
32 10 16 FDC ND No No No Alive, 3.5 M
33 11 18 FDC ND No No No Alive, 3.5 M
ANC indicates absolute neutrophil count; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Ext, extensive; Lim,
limited; MSCs, mesenchymal stem cells; FDC, full donor chimerism; MC, mixed chimerism; Pos, positive; Neg, negative; ND, not done; M, months.
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dentical transplantation by MA or NMA conditioning
[4,7,40]. It indicates that the modified haploidentical
NMA PBSCT with MSCs but without TCD may be
important in reducing leukemia relapse, which was
also further supported by the results of immunologic
reconstitution in the present study, which showed
that CD32CD(161 56)1 and CD31CD(161 56)1
cells were upregulated in 1 to 3 monthes after trans-
plantation.
Furthermore, in comparion with most other re-
ports [39,41], in which large amount (over 1 106/
kg) of MSCs were usually infused intravenously,
\1 106 cells/kg of MSCs were administered in 26
cases in this study, but the clinical outcome was better,Table 3. Immunological Cells Reconstitution in 33 Patients
CD3+CD4+CD82 CD3+CD42CD8+ CD4/CD8 CD32CD19+ CD3
pre 36.29 ± 15.02 33.40 ± 10.12 1.15 ± 0.50 2.5 ± 1.35 9
1 M 8.51 ± 7.70 27.58 ± 16.02 0.29 ± 0.24 5.29 ± 2.46 33
3 M 15.78 ± 5.13 43.30 ± 23.83 0.50 ± 0.36 1.35 ± 1.41 19
6 M 11.28 ± 5.37 54.22 ± 14.70 0.22 ± 0.12 1.75 ± 0.77 17
12 M 18.03 ± 6.77 65.65 ± 7.72 0.29 ± 0.13 2.10 ± 1.75 4
over18 M 13.43 ± 4.21 60.33 ± 9.29 0.23 ± 0.08 4.00 ± 3.90 11
Pre indicates pretransplantation, M, months.withmilder GVHD and stable engraftment, indicating
its still effective role. Moreover, Gao and coworkers
[42] even reported that mouse MSCs, when given in-
travenously, were blocked in the lungs and conse-
quently the homing of MSCs to BM is disturbed
[25]. The injection ofMSCs directly into bonemarrow
may markedly reduce peripheral residence of them,
that is, in lung and liver, indicating the advantage of
IBMI of MSCs.
In conclusion, our data demonstrate that the mod-
ified haploidentical transplantation combined with
MSCs for high-risk acute leukemia is effective in im-
proving donor engraftment and preventing severe
aGVHD, which may provide a feasible option for
treatment of high-risk acute leukemia.2CD (6 + 56)+ CD3+CD (16 + 56)+ CD3+CD4+CD25high CD3+HLA-DR+
.16 ± 5.38 6.06 ± 5.13 1.54 ± 1.06 5.25 ± 2.82
.13 ± 19.62 10.20 ± 8.52 0.61 ± 0.53 11.50 ± 7.15
.80 ± 15.53 7.45 ± 5.14 2.10 ± 1.92 26.83 ± 16.73
.82 ± 12.50 5.72 ± 2.21 1.32 ± 1.32 22.05 ± 21.25
.48 ± 0.62 4.45 ± 2.62 1.00 ± 0.69 22.42 ± 10.16
.83 ± 6.66 6.30 ± 0.51 1.13 ± 1.27 20.80 ± 10.20
936 Biol Blood Marrow Transplant 15:930-937, 2009M. Guo et al.ACKNOWLEDGMENTS
We thank Dr. Shimon Slavin for his critical read-
ing and modification of the manuscript. This work
was supported by grants from the ‘‘863 Projects’’ of
Ministry of Science and Technology of PR China
(No. 2006AA02A109); National Natural Science
Foundation of China (No. 30570771); China Medical
Board of New York, Stem Cell Biology, Engineering
(Grant No. 01-748); National Key Project for Basic
Research of China (No. 2001CB509907); and Cheung
Kong Scholars program. R.C.h. Zhao is a Cheung
Kong Scholar in P.R. China.
Authorship Statement
Mei Guo: conception and design, data analysis,
and interpretation; Zhao Sun, Qian Han, Bin Chen:
provision of study materials or patients; Qiyun Sun,
Changlin Yu, Danhong Wang, Jianhui Qiao, Lihui
Liu, and Wanjun Sun: provision of study materials or
patients; Kaixun Hu, Guangxian Liu, and Bing Liu:
manuscript writing; Robert C Zhao: conception and
design, financial support, provision of study materials
or patients; Huisheng Ai: conception and design, fi-
nancial support, administrative support, provision of
study materials or patients, collection and/or assembly
of data, data analysis and interpretation, manuscript
writing, and final approval of the manuscript.
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic
bone marrow transplants for leukemia using donors other than
HLA-identical siblings. J Clin Oncol. 1997;15:1767-1777.
2. Spitzer TR. Haploidentical stem cell transplantation: the always
present but overlooked donor. Hematology Am Soc Hematol Educ
Program. 2005;390-395.
3. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to conven-
tional bone marrow transplantation with lethal cytoreduction
for the treatment of malignant and nonmalignant hematologic
diseases. Blood. 1998;91:756-763.
4. Shimazaki C, Ochiai N, Uchida R, et al. Non-T-cell-depleted
HLAhaploidentical stem cell transplantation in advanced hema-
tologic malignancies based on the feto-maternal michrochimer-
ism. Blood. 2003;101:3334-3336.
5. Nakai K, Mineishi S, Kami M, Kanda Y, Tanosaki R, Takaue Y.
The feasibility of reduced-intensity allogeneic hematopoietic
stem cell transplantation from a related donor with HLA one-
antigen with or without one-allele mismatch. Haematologica.
2003;88:115-117.
6. Rizzieri DA, Koh LP, Long GD, et al. Partial matarched Non-
myeloablative allogenetic transplantation: clinical ouecome and
immune reconstitution. J Clin Oncol. 2007;25:690-697.
7. Lee CK, deMagalhaes-Silverman M, Hohl RJ, et al. Donor T-
lymphocyte infusion for unrelated allogeneic bone marrow
transplantation with CD31 T-cell-depleted graft. Bone Marrow
Transplant. 2003;31:121-128.
8. BethgeWA, Haegele M, Faul C, et al. Haploidentical allogeneic
hematopoietic cell transplantation in adult with reduced-inten-
sity conditioning and CD3/CD19 depletion: fast engraftment
and low toxicity. Exp Hematol. 2006;34:1746-1752.9. O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative
bone marrow transplantation from partially HLA-mismatched
related donors using posttransplantation cyclophophamide.
Biol Blood Marrow Transplant. 2002;8:377-386.
10. Blazsek I, Chagraoui J, Peault B. Ontogenic emergence of the
hematon, a morphogenetic stromal unit that supports multipo-
tential hematopoietic progenitors in mouse bone marrow. Blood.
2000;96:3763-3771.
11. Almeida-Porada G, Porada CD, Tran N, Zanjani ED. Cotrans-
plantation of human stromal cell progenitors into preimmune
fetal sheep results in early appearance of human donor cells in
circulation and boosts cell levels in bone marrow at later time
points after transplantation. Blood. 2000;95:3620-3627.
12. Anklesaria P, Kase K, Glowacki J, et al. Engraftment of a clonal
bone marrow stromal cell line in vivo stimulates hematopoietic
recovery from total body irradiation. Proc Natl Acad Sci USA.
1987;84:7681-7685.
13. NoortWA,Kruisselbrink AB, in’t Anker PS, et al. Mesenchymal
stem cells promote engraftment of human umbilical cord blood-
derived CD34(1) cells in NOD/SCID mice. Exp Hematol. 2002;
30:870-878.
14. Krampera M, Glennie S, Dyson J, et al. Bone marrow
mesenchymal stem cells inhibit the response of naive and mem-
ory antigen-specific T cells to their cognate peptide. Blood. 2003;
101:3722-3729.
15. Jiang XX, Zhang Y, Liu B, et al. Humanmesenchymal stem cells
inhibit differentiation and function of monocyte-derived den-
dritic cells. Blood. 2005;105:4120-4126.
16. Aggarwal S, Pittenger MF. Human mesenchymal stem cells
modulate allogeneic immune cell responses. Blood. 2005;105:
1815-1822.
17. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F,
MingariMC,Moretta L.Mesenchymal stem cells inhibit natural
killer-cell proliferation, cytotoxicity, and cytokine production:
role of indoleamine 2,3-dioxygenase and prostaglandin E2.
Blood. 2007;111:1327-1333.
18. Nauta AJ, FibbeWE. Immunomodulatory properties of mesen-
chymal stromal cells. Blood. 2007;110:3499-3506.
19. Le BlancK, Rasmusson I, Sundberg B, et al. Treatment of severe
acute graft-versus-host disease with third party haploidentical
mesenchymal stem cells. Lancet. 2004;363:1439-1441.
20. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of
ex vivo-expanded mesenchymal stem cells accelerates lympho-
cyte recovery and may reduce the risk of graft failure in haploi-
dentical hematopoietic stem-cell transplantation. Blood. 2007;
110:2764-2767.
21. Liu L, Sun Z, Chen B, et al. Ex vivo expansion and in vivo infu-
sion of bone marrow-derived Flk-1 1 CD312CD342 mesen-
chymal stem cells: feasibility and safety from monkey to
human. Stem Cells Dev. 2006;15:349-357.
22. Liu LH, Sun QY, Hu KX, et al. Establishment of Rhesus model
for haploidentical hematopoietic stem cell transplantation with
nonmyeloablative conditioning. Zhonghua Xue Ye Xue Za Zhi.
2005;26:385-388.
23. Majumdar MK, Thiede MA, Mosca JD, et al. Phenotypic
and functional comparison of culture of marrow-derived mes-
enchymal stem cells and stromal cells. J Cell Physiol. 1998;
176:57-66.
24. Fang B, Liao L, Shi M, Yang S, Zhao RC. Multipotency of
Flk1CD34 progenitors derived from human fetal bone marrow.
J Lab Clin Med. 2004;143:230-240.
25. Zhao Z, Liao L, Cao Y, Jiang X, Zhao RC. Establishment and
properties of fetal dermis-derived mesenchymal stem cell lines:
plasticity in vitro and hematopoietic protection in vivo. Bone
Marrow Transplant. 2005;36:355-365.
26. Hui-Sheng Ai, Chun-Hua Zhao Robert, Guo Mei, et al. Mixed
hematopoietic chimerism—a new strategy for preventing
GVHD in nonmyeloablative allogeneic stem cell transplanta-
tion. Exp Hematol. 2002;30:119.
27. Przepiorka D,Weisdorf D, Martin P, et al. 1994 consensus con-
ference on acuteGVHDgrading.BoneMarrow Transplant. 1995;
15:825-828.
Biol Blood Marrow Transplant 15:930-937, 2009 937Haploidentical NSTwith MSCs for Leukemia28. Mehta J, Singhal S, Gee AP, et al. Bone marrow transplantation
from partial HLA-mismatched family donors for acute leuke-
mia: single-center experience of 201 patients. Bone Marrow
Transplant. 2004;33:389-396.
29. Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem
cell transplantation from familymembers other thanHLA-iden-
tical siblings over the last decade (1991-2000). Blood. 2003;102:
1541-1547.
30. Tamaki H, Ikegame K, Kawakami1 M, et al. Engraftment of
HLA-haploidentical related transplants using nonmyeloablative
conditioning with fludarabine, busulfan and anti-T-lymphocyte
globulin. Leukemia. 2003;17:2052-2054.
31. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:
4119-4126.
32. BacigalupoA,LamparelliT, Bruzzi P, et al. Antithymocyte glob-
ulin for graft-versus-host disease prophylaxis in transplants from
unrelated donors: 2 randomized studies from Gruppo Italiano
Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942-2947.
33. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease
following allogeneic transplantation fromHLA-identical sibling
with antithymocyte globulin-based reduced-intensity prepara-
tive regimen. Blood. 2003;102:470-476.
34. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab
when combined with steroids for the treatment of acute graft-
versus-host disease: results of a randomized trial. Blood. 2004;
104:1559-1564.
35. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG,
WillemzeR, FibbeWE.Donor-derivedmesenchymal stem cells
are immunogenic in an allogeneic host and stimulate donor graftrejection in a nonmyeloablative setting. Blood. 2006;108:
2114-2120.
36. Shaffer J, Villard J, Means TK, et al. Regulary T-cell recovery in
receipients of Haploidentical nonmyeloablative hematopoietic
cell transplantation with a humanized anti-Cd2 mab, Medi-507,
with or without fludarabie. Exp Hematol. 2007;35:1140-1152.
37. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for
treatment of steroid-resistant, severe, acute graft-versus-host
disease: a phase II study. Lancet. 2008;371:1579-1586.
38. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of
HLA-identical sibling culture-expanded mesenchymal stem
cells and hematopoietic stem cell in hematologic malignancy
patients. Biol Blood Marrow Transplant. 2005;11:389-398.
39. Handgretinger R, Chen X, Pfeiffer M, et al. Feasibility and out-
come of reduced intensity conditioning in haploidentical trans-
plantation. Ann N Y Acad Sci. 2007;1106:279-289.
40. FungHC, Stein A, SlovakM, et al. A long-term follow-up report
on allogeneic stem cell transplantation for patients with primary
refractory acute myelogenous leukemia: impact of cytogenetic
characteristics on transplantation outcome. Biol Blood Marrow
Transplant. 2003;9:766-771.
41. Koc¸ ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic
recovery after coinfusion of autologous-blood stem cells and cul-
ture-expandedmarrowmesenchymal stemcells in advancedbreast
cancer patients receiving high-dose chemotherapy. J Clin Oncol.
2000;18:307-316.
42. Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distri-
bution of bonemarrow-derivedmesenchymal stem cells after in-
fusion. Cells Tissue Organs. 2001;169:12-20.
